Agency: Cordis | Branch: H2020 | Program: RIA | Phase: ICT-26-2014 | Award Amount: 4.07M | Year: 2015
Legionnaires disease is a serious form of pneumonia caused by bacterium Legionella pneumophila, with a case-fatality ratio on the order of 10-15%. L. pneumophila proliferates in aquatic habitats, especially in potable water, air conditioning, hot and cold water systems, cooling towers, evaporative condensers, spa/natural pools. Actually, its detection and monitoring rely on time-consuming protocols (in the order of several days) based on in-vitro selective bacteria culture methods, performed by highly specialized personnel in dedicated laboratories. POSEIDON project targets to change the approach in bacteriological environmental monitoring and in infection risk management by developing a fully automatic and reliable system. Handling of the air/water sample will be designed and integrated in preconditioning system and microfluidic device through which whole bacteria cells will be transported from the sampling module to the sensing plasmonic surface. The complete measure protocol will be integrated and performed according to EU legislation guidelines. Specificity will be ensured by immuno-functionalization of gratings surfaces and enhanced system sensitivity will be granted by the optimization of the optical detection system architecture. Sensors based on Grating Coupled Surface Plasmon Resonance (GC-SPR) in azimuthally rotating configuration have recently proved sensitivity enhancement up to almost two orders of magnitude. Furthermore, the symmetry breaking related to grating rotation allows exploiting the incident polarization, more easily controlled with respect to incidence wavelength and angles interrogation. The prototype will be designed to be integrated in water distribution or HVAC systems in order to demonstrate its feasibility in industrially relevant fields and to open new applications and new market opportunities. POSEIDON project aims to address new solutions in this relevant health and safety societal challenge.
Agency: Cordis | Branch: FP7 | Program: CSA-CA | Phase: NMP.2012.1.2-3 | Award Amount: 1.77M | Year: 2012
Nanomedicine, the application of nanotechnology to health, is a fast-growing field with a large potential for improving diagnostics and therapeutic solutions in many diseases. The EuroNanoMed II (ENM II) consortium, with 20 partners from 17 countries and regions, aims to foster the competitiveness of European nanomedicine actors through the support of translational research projects enhancing transnational and multidisciplinary collaborations between academia, clinical/public health communities and industry. ENM II will be a follow-up of the ERA-NET EuroNanoMed I (ENM I), which launched three joint transnational calls for proposals in three years. The increasing number of submitted proposals in the successive ENM I joint calls and their quality show the need amongst the nanomedicine scientific community for such a targeted initiative. ENM II will be built on the basis of the ENM I accomplishments, and will continue to support transnational innovative RTD projects in nanomedicine through the launch of yearly joint calls for proposals. In addition, ENM II aims to extend the cooperation among its partners through the development of other activities: (i) foster the participation of young European researchers to ENM II activities; ii) develop a strategic agenda for ENM II in close cooperation to the ETP Nanomedicine; iii) create more interactions within the European nanomedicine community and improve communication on nanomedicine to the public; iv) frame and address regulatory, safety and ethical issues associated with nanomedicine; v) monitor the results of the ENM I & ENM II funded research projects and the activities of the ENM II network; and, vi) develop a long-term cooperation framework for European nanomedicine research. Therefore, through joint funding of translational nanomedicine projects and its other activities, ENM II will contribute to enhance coordination of research and resources in this field, thereby shaping the European Research Area in nanomedicine.
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: NMP.2012.1.3-3 | Award Amount: 49.52M | Year: 2013
The innovative and economic potential of Manufactured Nano Materials (MNMs) is threatened by a limited understanding of the related EHS issues. While toxicity data is continuously becoming available, the relevance to regulators is often unclear or unproven. The shrinking time to market of new MNM drives the need for urgent action by regulators. NANoREG is the first FP7 project to deliver the answers needed by regulators and legislators on EHS by linking them to a scientific evaluation of data and test methods. Based on questions and requirements supplied by regulators and legislators, NANoREG will: (i) provide answers and solutions from existing data, complemented with new knowledge, (ii) Provide a tool box of relevant instruments for risk assessment, characterisation, toxicity testing and exposure measurements of MNMs, (iii) develop, for the long term, new testing strategies adapted to innovation requirements, (iv) Establish a close collaboration among authorities, industry and science leading to efficient and practically applicable risk management approaches for MNMs and products containing MNMs. The interdisciplinary approach involving the three main stakeholders (Regulation, Industry and Science) will significantly contribute to reducing the risks from MNMs in industrial and consumer products. NANoREG starts by analysing existing knowledge (from WPMN-, FP- and other projects). This is combined with a synthesis of the needs of the authorities and new knowledge covering the identified gaps, used to fill the validated NANoREG tool box and data base, conform with ECHAs IUCLID DB structure. To answer regulatory questions and needs NANoREG will set up the liaisons with the regulation and legislation authorities in the NANoREG partner countries, establish and intensify the liaisons with selected industries and new enterprises, and develop liaisons to global standardisation and regulation institutions in countries like USA, Canada, Australia, Japan, and Russia.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: NMP-26-2014 | Award Amount: 10.67M | Year: 2015
One of the greatest challenges facing regulators in the ever changing landscape of novel nano-materials is how to design and implement a regulatory process which is robust enough to deal with a rapidly diversifying system of manufactured nanomaterials (MNM) over time. Not only does the complexity of the MNM present a problem for regulators, the validity of data decreases with time, so that the well-known principle of the half-life of facts (Samuel Arbesman, 2012) means that what is an accepted truth now is no longer valid in 20 or 30 years time. The challenge is to build a regulatory system which is flexible enough to be able to deal with new targets and requirements in the future, and this can be helped by the development and introduction of Safe by Design (SbD) principles. The credibility of such a regulatory system, underpinned by the implementation of SbD, is essential for industry, who while accepting the need for regulation demand it is done in a cost effective and rapid manner. The NANoREG II project, built around the challenge of coupling SbD to the regulatory process, will demonstrate and establish new principles and ideas based on data from value chain implementation studies to establish SbD as a fundamental pillar in the validation of a novel MNM. It is widely recognized by industries as well as by regulatory agencies that grouping strategies for NM are urgently needed. ECETOC has formed a task force on NM grouping and also within the OECD WPMN a group works on NM categorisation. However, so far no reliable and regulatory accepted grouping concepts could be established. Grouping concepts that will be developed by NanoREG II can be regarded as a major innovation therefore as guidance documents on NM grouping will not only support industries or regulatory agencies but would also strongly support commercial launch of new NM.
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: NMP-2010-1.3-1 | Award Amount: 13.15M | Year: 2011
The growing development, production and use of engineered nanomaterials and associated products will increase exposure of both humans and ecosystems to these new materials. However, current knowledge is still incomplete and established test methods are as yet inappropriate to reliably assess the extent of exposure and risk of materials at the nano-scale. There is an urgent need to develop methods to overcome the current limitations of existing hazard and risk assessment schemes and to generate the body of reference data needed as the basis for regulative requirements and for measures to safeguard production, application and the disposal of nanomaterials. The proposed project will mobilize the critical mass of international scientific knowledge and technical expertise required to address these questions. Current analytical and toxicity test methods and models will be put to test and subjected to rigorous intercalibration and validation. Where necessary, methods and test materials will be modified, adapted and validated, and new reliable reference methods developed, in cooperation with international standardisation bodies and the concerned industry, to support both pre and co-normative activities and to make the applicability of existing RA and LCA schemes to ENPs more reliable. The feasibility of validated measurement, characterization and test methods will be assessed by selected case studies to help the significant improvement of the performance of existing exposure monitoring systems as well as the development of new risk management and reduction strategies.